211738-66-8

Basic information

• Product Name: 4-BROMO-1-METHYL-1 H-PYRAZOLE-3-CARBOXYLIC ACID M ETHYL ESTER
• Synonyms: RARECHEM AL BF 1005;ART-CHEM-BB B001423;4-BROMO-1-METHYL-1 H-PYRAZOLE-3-CARBOXYLIC ACID M ETHYL ESTER;AKOS B001423;methyl 4-bromo-1-methyl-1H-pyrazole-3-carboxylate;1H-pyrazole-3-carboxylic acid, 4-bromo-1-methyl-, methyl e;methyl 4-bromo-1-methyl-1H-pyrazole-3-carboxylate(SALTDATA: FREE);4-bromo-1-methyl-3-pyrazolecarboxylic acid methyl ester
• CAS NO: 211738-66-8
• Molecular Formula: C₆H₇BrN₂O₂
• Molecular Weight: 219.04
• Mol File: 211738-66-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 276.5 °C at 760 mmHg
• Flash Point: 121 °C
• Appearance: /
• Density: 1.67 g/cm³
• Vapor Pressure: 0.00477mmHg at 25°C
• Refractive Index: 1.589
• Storage Temp.: 2-8°C
• PKA: -2.22±0.10(Predicted)
• CAS DataBase Reference: 4-BROMO-1-METHYL-1 H-PYRAZOLE-3-CARBOXYLIC ACID M ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-1-METHYL-1 H-PYRAZOLE-3-CARBOXYLIC ACID M ETHYL ESTER(211738-66-8)
• EPA Substance Registry System: 4-BROMO-1-METHYL-1 H-PYRAZOLE-3-CARBOXYLIC ACID M ETHYL ESTER(211738-66-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 211738-66-8(Hazardous Substances Data)

Usage

General Description

4-Bromo-1-methyl-1H-pyrazole-3-carboxylic acid methyl ester is a chemical compound that belongs to the class of pyrazole derivatives. Its molecular formula is C7H8BrN3O2 and it has a molecular weight of 231.06 g/mol. 4-BROMO-1-METHYL-1 H-PYRAZOLE-3-CARBOXYLIC ACID M ETHYL ESTER is a methyl ester derivative of 4-bromo-1-methyl-1H-pyrazole-3-carboxylic acid and is commonly used in the field of organic synthesis and medicinal chemistry. It may be used as a building block for the synthesis of various pharmaceutical compounds and biologically active molecules. The presence of the bromo group and the carboxylic acid functionality in its structure make it a valuable intermediate for the preparation of diverse chemical compounds.

InChI:InChI=1/C6H7BrN2O2/c1-9-3-4(7)5(8-9)6(10)11-2/h3H,1-2H3

Upstream product

• 138786-86-4 methyl 4-nitro-1H-pyrazole-3-carboxylate 
• 400877-57-8 1-methyl-4-nitro-1H-pyrazole-3-carboxylic acid methyl ester 
• 637336-53-9 4-amino-1-methyl-1H-pyrazole-3-carboxylic acid methyl ester 
• 13745-17-0 4-bromo-1H-pyrazole-3-carboxylic acid 
• 74-88-4 methyl iodide 
• 81190-89-8 methyl 4-bromo-1H-pyrazole-3-carboxylate 
• 4598-86-1 1-methyl-4-nitro-1H-pyrazole-3-carboxylic acid 

Downstream Products

• 915707-65-2 (4-bromo-1-methyl-1H-pyrazol-3-yl)methanol 
• 1383572-91-5 9-(4,6-dimethylpyrimidin-2-yl)-4-((1-methyl-4-phenyl-1H-pyrazol-3-yl)methyl)-1,4,9-triazaspiro[5.5]undecan-5-one 
• 96256-54-1 methyl 1-methyl-4-phenyl-1H-pyrazole-3-carboxylate 

Relevant articles and documents

SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

Fused 3-hydroxy-3-trifluoromethylpyrazoles inhibit mutant huntingtin toxicity

Here, we describe the selection and optimization of a chemical series active in both a full-length and a fragment-based Huntington's disease (HD) assay. Twenty-four thousand small molecules were screened in a phenotypic HD assay, identifying a series of compounds bearing a 3-hydroxy-3- trifluoromethylpyrazole moiety as able to revert the toxicity induced by full-length mutant Htt by up to 50%. A chemical exploration around the series led to the identification of compound 4f, which demonstrated to be active in a Htt171-82Q rat primary striatal neuron assay and a PC12-Exon-1 based assay. This compound was selected for testing in R6/2 mice, in which it was well-tolerated and showed a positive effect on body weight and a positive trend in preventing ventricular volume enlargment. These studies provide strong rationale for further testing the potential benefits of 3-hydroxy-3-trifluoromethylpyrazoles in treating HD.